Friday, May 24, 2019
wellness India Expo
Home Tags Biocon

Tag: Biocon

Riding on biologics wave, Biocon registers two fold growth during FY...

For the fiscal year ended March 2019, the Biocon's net profit rose over two-fold to Rs 905.3 crore as against Rs 372.4 crore for 2017-18. Company registered 64% growth in Q4 of FY19, earning 214 cr in net profits.................

Women must be encouraged to become entrepreneurs: Kiran Shaw

Speaking at the interactive session ‘An Empowering story, entrepreneurial journey of Dr Kiran Mazumdar’ organized by FICCI Ladies Organization, Dr Kiran Mazumdar Shaw, Chairperson, Biocon Limited revealed that her company aims to soon expand its presence in the pioneering field of biosimilars in US market....................

Deakin University to felicitate Kiran Mazumdar Shaw with honorary doctorate

The Honorary Doctorate is to felicitate Ms Mazumdar-Shaw's long-spanning achievement in the field of health, science and technology............................

Biocon & Mylan announce positive CHMP opinion for Ogivri, biosimilar Trastuzumab

The endorsement by European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) opens up opportunities towards tapping approximately $1.9 billion market for the product in Europe...………….

Biocon’s indigenous biologic for head & neck cancer a viable solution,...

At a panel discussion held by the Biocon at New Delhi, the leading oncologists deliberated on the results of a large scale clinical study on novel biologic, BioMab EGFR (Nimotuzumab) for head and neck cancer and its impact as a targeted therapy on patient outcomes

Biocon Chief Kiran Shaw to join Board of Trustees of MIT,...

Starting 1st July 2018, the Chairperson and Managing Director of India's biggest biotech corporation, Kiran Mazumdar Shaw will serve a five-year term on the Massachusetts Institute of Technology Corporation................

Biocon receives EIR from USFDA for its Bengaluru facility

The US Food and Drug Administration (USFDA) has sent the report citing closure of inspection of Biocon's sterile drug product manufacturing facility in Bengaluru............

Vasudev Tribhuvan joins Wellthy Therapeutics as VP-Partnerships & Alliances

Vasudev’s previous role was at Biocon, where he was the Senior Director, Marketing and led strategic initiatives for the metabolic unit while guiding the team on patient programs..............

US FDA approves Mylan & Biocon’s biosimilar, Fulphila

Second FDA-approved biosimilar through the Mylan-Biocon collaboration,, Fulphila is expected to be the first biosimilar pegfilgrastim available in the U.S. to help patients with nonmyeloid cancers reduce the risk of infection...............

Shrikumar Suryanarayan of Sea6Energy takes over as ABLE President

A new team of elected Executive Council, led by Mr Shrikumar Suryanarayan, chairman of Sea6Energy, as President has taken charge at the Association of Biotechnology Led Enterprises (ABLE) on April 1, 2018............